162 related articles for article (PubMed ID: 8224241)
21. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
22. In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1.
Williams CR; Sykes JE; Mehl M; MacLeod JS; Lindsay LL; Poland AM; Chen YJ; Kyles AE; Waldman WJ; Gregory CR
Am J Vet Res; 2007 Sep; 68(9):1010-5. PubMed ID: 17764417
[TBL] [Abstract][Full Text] [Related]
23. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
[TBL] [Abstract][Full Text] [Related]
24. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes.
Burger D; Begué-Pastor N; Benavent S; Gruaz L; Kaufmann MT; Chicheportiche R; Dayer JM
Rheumatology (Oxford); 2003 Jan; 42(1):89-96. PubMed ID: 12509619
[TBL] [Abstract][Full Text] [Related]
25. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.
Cutolo M; Sulli A; Ghiorzo P; Pizzorni C; Craviotto C; Villaggio B
Ann Rheum Dis; 2003 Apr; 62(4):297-302. PubMed ID: 12634225
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
27. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.
Xu X; Williams JW; Gong H; Finnegan A; Chong AS
Biochem Pharmacol; 1996 Aug; 52(4):527-34. PubMed ID: 8759024
[TBL] [Abstract][Full Text] [Related]
28. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
[TBL] [Abstract][Full Text] [Related]
29. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Kirsch BM; Zeyda M; Stuhlmeier K; Grisar J; Smolen JS; Watschinger B; Stulnig TM; Hörl WH; Zlabinger GJ; Säemann MD
Arthritis Res Ther; 2005; 7(3):R694-703. PubMed ID: 15899055
[TBL] [Abstract][Full Text] [Related]
30. An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes.
Migita K; Miyashita T; Maeda Y; Nakamura M; Yatsuhashi H; Ishibashi H; Eguchi K
Rheumatology (Oxford); 2005 Apr; 44(4):443-8. PubMed ID: 15695308
[TBL] [Abstract][Full Text] [Related]
31. [Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritoneal macrophages].
Ju DW; Zheng QY; Wang HB; Fang J
Yao Xue Xue Bao; 1994; 29(2):90-4. PubMed ID: 8042517
[TBL] [Abstract][Full Text] [Related]
32. Ganglioside GM3 inhibition of EGF receptor mediated signal transduction.
Rebbaa A; Hurh J; Yamamoto H; Kersey DS; Bremer EG
Glycobiology; 1996 Jun; 6(4):399-406. PubMed ID: 8842703
[TBL] [Abstract][Full Text] [Related]
33. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
Nair RV; Cao W; Morris RE
Immunol Lett; 1995 Dec; 48(2):77-80. PubMed ID: 8719103
[TBL] [Abstract][Full Text] [Related]
35. In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can be inhibited by leflunomide's active metabolite A77 1726.
Schorlemmer HU; Kurrle R; Schleyerbach R; Bartlett RR
Inflamm Res; 1999 Dec; 48 Suppl 2():S111-2. PubMed ID: 10667839
[No Abstract] [Full Text] [Related]
36. A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools.
Huang M; Wang Y; Collins M; Mitchell BS; Graves LM
Mol Pharmacol; 2002 Sep; 62(3):463-72. PubMed ID: 12181422
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
Nair RV; Cao W; Morris RE
Immunol Lett; 1995 Sep; 47(3):171-4. PubMed ID: 8747714
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.
Kraan MC; Smeets TJ; van Loon MJ; Breedveld FC; Dijkmans BA; Tak PP
Ann Rheum Dis; 2004 Sep; 63(9):1056-61. PubMed ID: 15115713
[TBL] [Abstract][Full Text] [Related]
39. Sex hormones modulate the effects of Leflunomide on cytokine production by cultures of differentiated monocyte/macrophages and synovial macrophages from rheumatoid arthritis patients.
Cutolo M; Montagna P; Brizzolara R; Sulli A; Seriolo B; Villaggio B; Triolo P; Clerico P; Soldano S
J Autoimmun; 2009; 32(3-4):254-60. PubMed ID: 19324522
[TBL] [Abstract][Full Text] [Related]
40. Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases.
Mangold U; Dax CI; Saar K; Schwab W; Kirschbaum B; Müllner S
Eur J Biochem; 1999 Dec; 266(3):1184-91. PubMed ID: 10583416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
